Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 54

1.

Impact of CYP2C19 polymorphism and proton pump inhibitors on platelet reactivity to clopidogrel and clinical outcomes following stent implantation.

Hokimoto S, Mizobe M, Akasaka T, Arima Y, Kaikita K, Nakagawa K, Ogawa H.

Thromb Res. 2014 Apr;133(4):599-605. doi: 10.1016/j.thromres.2014.01.003. Epub 2014 Jan 9.

PMID:
24440142
[PubMed - indexed for MEDLINE]
2.

Identifying responsiveness to oral P2Y12 receptor blockers: platelet function assays and genetic tests.

Valgimigli M.

J Cardiovasc Med (Hagerstown). 2013 Dec;14 Suppl 1:S8-S15. doi: 10.2459/JCM.0b013e328364bd25. Review.

PMID:
24378839
[PubMed - indexed for MEDLINE]
3.

Potential clinical utility of genetic and platelet function tests in patients on treatment with clopidogrel.

Cattaneo M.

J Cardiovasc Med (Hagerstown). 2013 Dec;14 Suppl 1:S16-21. doi: 10.2459/JCM.0b013e328364bd3a. Review.

PMID:
24378837
[PubMed - indexed for MEDLINE]
4.

Response variability to P2Y12 receptor inhibitors: expectations and reality.

Siller-Matula JM, Trenk D, Schrör K, Gawaz M, Kristensen SD, Storey RF, Huber K; EPA (European Platelet Academy).

JACC Cardiovasc Interv. 2013 Nov;6(11):1111-28. doi: 10.1016/j.jcin.2013.06.011. Review.

PMID:
24262612
[PubMed - indexed for MEDLINE]
Free Article
5.

Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways.

Braun OÖ, Angiolillo DJ, Ferreiro JL, Jakubowski JA, Winters KJ, Effron MB, Duvvuru S, Costigan TM, Sundseth S, Walker JR, Saucedo JF, Kleiman NS, Varenhorst C.

Thromb Haemost. 2013 Dec;110(6):1223-31. doi: 10.1160/TH13-03-0263. Epub 2013 Sep 5.

PMID:
24009042
[PubMed - indexed for MEDLINE]
6.

PON1 Q192R genotype influences clopidogrel responsiveness by relative platelet inhibition instead of on-treatment platelet reactivity.

Li X, Zhang L, Chen X, Qu F, Li J, Ma C, Yang J, Xu B, Wang H, Xu Q, Zhang Y, Li Y, Lu C, Yin T.

Thromb Res. 2013 Oct;132(4):444-9. doi: 10.1016/j.thromres.2013.08.004. Epub 2013 Aug 9.

PMID:
23993903
[PubMed - indexed for MEDLINE]
7.

Defining predictive values using three different platelet function tests for CYP2C19 phenotype status on maintenance dual antiplatelet therapy after PCI.

Zhang HZ, Kim MH, Han JY, Jeong YH.

Platelets. 2014;25(4):285-91. doi: 10.3109/09537104.2013.815340. Epub 2013 Aug 23.

PMID:
23971745
[PubMed - indexed for MEDLINE]
8.

[Relevance of CYP2C19 2 regarding platelet reactivity in patients with acute coronary syndrome treated with clopidogrel].

Cano P, Consuegra-Sánchez L, Conesa P, Torres-Moreno D, Jaulent L, Dau D, Picó F, Villegas M.

Med Clin (Barc). 2014 Jul 7;143(1):6-12. doi: 10.1016/j.medcli.2013.04.042. Epub 2013 Jul 10. Spanish.

PMID:
23850044
[PubMed - indexed for MEDLINE]
9.

Impact of the proton pump inhibitors and CYP2C19*2 polymorphism on platelet response to clopidogrel as assessed by four platelet function assays.

Tsantes AE, Ikonomidis I, Papadakis I, Bonovas S, Gialeraki A, Kottaridi C, Kyriakou E, Kokori S, Douramani P, Kopterides P, Karakitsos P, Lekakis J, Kapsimali V.

Thromb Res. 2013 Aug;132(2):e105-11. doi: 10.1016/j.thromres.2013.06.015. Epub 2013 Jul 2.

PMID:
23830212
[PubMed - indexed for MEDLINE]
10.

P2Y12 receptor gene polymorphism and antiplatelet effect of clopidogrel in patients with coronary artery disease after coronary stenting.

Zoheir N, Abd Elhamid S, Abulata N, El Sobky M, Khafagy D, Mostafa A.

Blood Coagul Fibrinolysis. 2013 Jul;24(5):525-31. doi: 10.1097/MBC.0b013e32835e98bf.

PMID:
23751603
[PubMed - indexed for MEDLINE]
11.

Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients.

Zhang L, Chen Y, Jin Y, Qu F, Li J, Ma C, Yang J, Xu B, Wang H, Li X, Li Y, Zhang Y, Lu C, Yin T.

Thromb Res. 2013 Jul;132(1):81-7. doi: 10.1016/j.thromres.2013.05.006. Epub 2013 May 29.

PMID:
23726091
[PubMed - indexed for MEDLINE]
12.

Cytochrome P450 2B6 and 2C9 genotype polymorphism--a possible cause of prasugrel low responsiveness.

Franken CC, Kaiser AF, Krüger JC, Overbeck K, Mügge A, Neubauer H.

Thromb Haemost. 2013 Jul;110(1):131-40. doi: 10.1160/TH13-01-0021. Epub 2013 Apr 25.

PMID:
23615745
[PubMed - indexed for MEDLINE]
13.

Letter by Alexopoulos et al regarding article, "pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel dose versus prasugrel: the RESET GENE Trial".

Alexopoulos D, Xanthopoulou I.

Circ Cardiovasc Interv. 2013 Feb;6(1):e11. doi: 10.1161/CIRCINTERVENTIONS.112.975953. No abstract available.

PMID:
23424274
[PubMed - indexed for MEDLINE]
Free Article
14.

The impact of CYP2C19 genotype on cardiovascular events and platelet reactivity in patients with coronary artery disease receiving clopidogrel.

Tousoulis D, Siasos G, Zaromitidou M, Oikonomou E, Maniatis K, Kioufis S, Kokkou E, Papavassiliou AG, Stefanadis C.

Int J Cardiol. 2013 Sep 30;168(2):1594-6. doi: 10.1016/j.ijcard.2013.01.040. Epub 2013 Feb 10. No abstract available.

PMID:
23402725
[PubMed - indexed for MEDLINE]
15.

Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications.

Grosdidier C, Quilici J, Loosveld M, Camoin L, Moro PJ, Saut N, Gaborit B, Pankert M, Cohen W, Lambert M, Beguin S, Morange PE, Bonnet JL, Alessi MC, Cuisset T.

Am J Cardiol. 2013 Apr 1;111(7):985-90. doi: 10.1016/j.amjcard.2012.12.013. Epub 2013 Jan 19.

PMID:
23340030
[PubMed - indexed for MEDLINE]
16.

Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study.

Saucedo JF, Angiolillo DJ, DeRaad R, Frelinger AL 3rd, Gurbel PA, Costigan TM, Jakubowski JA, Ojeh CK, Duvvuru S, Effron MB; SWAP Investigators.

Thromb Haemost. 2013 Feb;109(2):347-55. doi: 10.1160/TH12-06-0378. Epub 2012 Dec 6.

PMID:
23223867
[PubMed - indexed for MEDLINE]
17.

Clinical impact of genetically determined platelet reactivity.

Laine M, Arméro S, Peyrol M, Sbragia P, Thuny F, Paganelli F, Bonello L.

J Cardiovasc Transl Res. 2013 Jun;6(3):398-403. doi: 10.1007/s12265-012-9421-4. Epub 2012 Nov 13. Review.

PMID:
23149816
[PubMed - indexed for MEDLINE]
18.

Near patient anti-platelet response testing over time and gene analysis in patients admitted with acute coronary syndromes.

Amoah V, Storey RF, Worrall AP, Goodridge K, Lovatt T, Smallwood A, Armesilla AL, Nevill AM, Cotton JM.

Platelets. 2013;24(8):643-8. doi: 10.3109/09537104.2012.733046. Epub 2012 Nov 13.

PMID:
23148794
[PubMed - indexed for MEDLINE]
19.

Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial.

Sardella G, Calcagno S, Mancone M, Palmirotta R, Lucisano L, Canali E, Stio RE, Pennacchi M, Di Roma A, Benedetti G, Guadagni F, Biondi-Zoccai G, Fedele F.

Circ Cardiovasc Interv. 2012 Oct;5(5):698-704. doi: 10.1161/CIRCINTERVENTIONS.112.972463. Epub 2012 Oct 9.

PMID:
23048056
[PubMed - indexed for MEDLINE]
Free Article
20.

Effects of CYP2C19 variant alleles on postclopidogrel platelet reactivity and clinical outcomes in an actual clinical setting in China.

Wu H, Qian J, Xu J, Sun A, Sun W, Wang Q, Ge J.

Pharmacogenet Genomics. 2012 Dec;22(12):887-90. doi: 10.1097/FPC.0b013e328359253a.

PMID:
22990067
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk